In GO, IDO1 has multiple bioactivities in BLCA, CESC, BRCA, GBM, KIRP, HNSC, LAML and LGG with diverse modulating effects on patient prognosis; for instance: T cell tolerance induction, regulation of lymphocyte-mediated immunity, immunoglobulin complex circulating, T cell receptor complex, negative regulation of tumor necrosis factor secretion, FC receptor-mediated stimulatory signaling pathway, B cell receptor signaling pathway (Fig. 9A). The gene discussed is TNF; the disease is bladder transitional cell carcinoma.